Orbis Medicines

Explore the latest insights on Orbis Medicines and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Orbis Medicines’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medical Wei (Shenzhen) Biotechnology Co., Ltd. ("Medicovestor"), wholly owned by MEDICOVESTOR SDN BHD, announced the completion of a seed financing round of several million RMB, led by Tongmengzhe (Shenzhen) Pharmaceutical…

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now